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Summary
 
It has been proposed that the increase in prevalence and severity of atopic disorders inversely
correlates with exposure to infectious diseases such as tuberculosis. We have investigated this is-
sue by combining an intranasal 
 
Mycobacterium bovis
 
–Bacillus Calmette-Guérin (BCG) infection
with a murine model of allergen, (ovalbumin [OVA]) induced airway eosinophilia. BCG infec-
tion either 4 or 12 wk before allergen airway challenge resulted in a 90–95 and 60–70% reduc-
tion in eosinophilia within the lungs, respectively, compared to uninfected controls. The inhi-
bition of airway eosinophilia correlated with a reduced level of IL-5 production by T cells from
the lymph node draining the site of OVA challenge. Interestingly, BCG infection of the lung
had no effect on IgG1 and IgE OVA-specific serum immunoglobulin or blood eosinophil lev-
els. Furthermore, BCG-induced inhibition of airway eosinophilia was strongly reduced in in-
terferon (IFN)-
 
g
 
 receptor–deficient mice and could be partially reversed by intranasal IL-5 ap-
plication. Intranasal BCG infections could also reduce the degree of lung eosinophilia and IL-5
produced by T cells after 
 
Nippostrongylus brasiliensis
 
 infection. Taken together, our data suggest
that IFN-
 
g
 
 produced during the T helper cell (Th)1 immune response against BCG suppresses
the development of local inflammatory Th2 responses in the lung. Most importantly, this inhi-
bition did not extend to the systemic immunoglobulin response against OVA. Our data sup-
port the view that mycobacterial infections have the potential to suppress the development of
atopic disorders in humans.
 
A
 
sthma is an atopic disorder characterized by activation
and recruitment of eosinophils to the lung resulting in
chronic swelling and inflammation of the airways. The pro-
cesses leading to allergic inflammation are controlled by the
Th2 lymphocytes (1–4), which secrete IL-4 and IL-5 lead-
ing to enhanced production of IgE by B cells and the gen-
eration and recruitment of eosinophils, respectively (5–9).
Th2 responses predominate in individuals suffering from
atopic disorders or helminthic infections (3, 6, 9).
Atopic disorders, in particular asthma, are steadily in-
creasing, with 
 
z
 
20–30% of the population in developed
countries affected (10–12). The reasons for the increase are
not known, although it has been noticed that the increase
in atopic disorders inversely correlates with a steady decline
in the extent to which the population is exposed to major
human diseases such as tuberculosis, measles, whooping cough,
and influenza (11, 13). One of the general features of these
infectious agents is that they induce characteristic Th1 type
immune responses, which lead to an immunological envi-
ronment rich in IFN-
 
g
 
 (6, 7, 14–16). As IFN-
 
g
 
 is viewed
as a powerful suppressive mediator of Th2 activity, the lack
of frequent exposure to such infections has been speculated
to increase the risk of developing atopy (6, 7, 11, 13). Sup-
porting this hypothesis has been a recent report demon-
strating an inverse relationship between atopy and infection
with, or exposure to, 
 
Mycobacterium tuberculosis
 
 (13). How-
ever, these data do not confirm that mycobacterial infec-
tions reduce predisposition to atopy as genetic factors con-
tributing to susceptibility for atopy or tuberculosis could be
mutually exclusive.
In this report we address the question of whether an in-
fection with an attenuated form of 
 
Mycobacterium bovis
 
, Ba-
cillus Calmette-Guérin (BCG),
 
1
 
 can suppress the develop-
ment of type 2 immune responses in the lungs of mice. For
this purpose we infected mice intranasally with BCG and
investigated whether these animals could generate Th2s
 
1
 
Abbreviations used in this paper:
 
 BAL, bronchoalveolar lavage; BCG, Bacil-
lus Calmette-Guérin; MLN, mediastinal LN; PPD, purified protein de-
rivative; RT, room temperature.
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leading to the accumulation of eosinophils into the airways.
Type 2 responses in the lung were either induced by OVA
challenge (17) or by infection with the helminth 
 
Nippo-
strongylus brasiliensis
 
 (18). In both cases the immune re-
sponse is characterized by the accumulation of eosinophils
into the airways and increased IgE serum levels, and corre-
lates with the appearance of airway hyperresponsiveness
(19). Here we show that a BCG infection of the lung
strongly inhibits the development of airway eosinophilia
and that this effect was dependent upon IFN-
 
g
 
 signaling.
 
Materials and Methods
 
Mice.
 
C57Bl/6J mice were bred and housed at the Wellington
School of Medicine Animal Facility (Wellington, New Zealand).
The IFN-
 
g
 
R
 
2
 
/
 
2
 
 and IFN-
 
g
 
R
 
1
 
/
 
1
 
 129/Sv/Ev mice were a gift from
M. Aguet (University of Zurich, Zurich, Switzerland; reference
20). All animals used in the experiments were between 5 and 7
wk of age. The experimental procedures were approved by the
animal ethics committee and were in accordance with University
of Otago (Dunedin, New Zealand) guidelines for the care of animals.
 
OVA-induced Airway Inflammation.
 
Mice were injected intra-
peritoneally with 2 
 
m
 
g OVA (Sigma Chemical Co., St. Louis,
MO) in 100 
 
m
 
l alum adjuvant (Serva, Heidelberg, Germany) on
day 0 and boosted again intraperitoneally with 2 
 
m
 
g OVA/alum
at day 14. 14 d after the second intraperitoneal immunization,
mice were anesthetized by injection of a mixture of Ketamine
and Xylazine (Sigma Chemical Co.), and 100 
 
m
 
g OVA in a 50-
 
m
 
l
volume of PBS was administered by intranasal inoculation. Where
indicated, rIL-5 (500 Units; Genzyme Corp., Cambridge, MA)
was included in the PBS containing the OVA.
 
Infection of Mice with BCG or N. brasiliensis.
 
Mice were either
infected intranasally, intraperitoneally, or subcutaneously with the
indicated numbers of viable CFUs of BCG (Connaught, Willow-
dale, Canada). Mice were anesthetized as described above, to fa-
cilitate the intranasal infection. 
 
N. brasiliensis
 
 (1,000 L3 larvae)
were injected intraperitoneally to establish infection.
 
Detection of Different Cell Types in the Blood and Bronchoalveolar
Lavage Fluid.
 
At the indicated time points after intranasal OVA
challenge or 
 
N. brasiliensis
 
 infection, the mice were killed. Blood
smears were prepared, the trachea cannulated, and bronchoalveo-
lar lavage (BAL) performed by flushing lung and airways 3 times
with 1 ml PBS. BAL cells were counted and spun onto glass slides
using a cytospin (Shandon Southern Products Ltd., Asmoor, UK) to-
gether with the blood smears stained with Dif-Quik (Dade, Aguada,
Puerto Rico) according to the manufacturer’s instructions. Per-
centages of macrophages, lymphocytes, neutrophils, and eosino-
phils were determined microscopically using standard histological
criteria.
 
Culture Conditions of Cells.
 
Single-cell suspensions from the
mediastinal LNs (MLN) (2 
 
3
 
 10
 
6
 
 cells/ml) of the different groups of
mice were prepared and cultured in IMDM medium (Sigma Chem-
ical Co.) supplemented with sodium bicarbonate (3.024 g/liter),
10 
 
m
 
g/ml streptomycin, 10 units/ml penicillin, 50 
 
m
 
M 2-mer-
captoethanol, and 10% fetal calf serum. The cell preparations
were either stimulated with 10 
 
m
 
g/ml purified protein derivative
(PPD) from 
 
M. bovis
 
 (Commonwealth Serum Laboratories, Vic-
toria, Australia) or in microwells coated with a monoclonal anti-
body to CD3
 
e
 
 (145-2C11, 25 
 
m
 
g/ml) together with 200 units/ml
recombinant human IL-2 (Ciba-Geigy, Basel, CH). After 48 h,
the culture supernatants were harvested and tested for the pres-
ence of cytokines by ELISA.
 
Proliferation Assay.
 
Cells were cultured in microwells in the
presence of medium alone, 10 
 
m
 
g/ml PPD (Commonwealth Se-
rum Laboratories) or 5 
 
m
 
g/ml of Con A for 40 h. Proliferative re-
sponses were determined by [
 
3
 
H]thymidine (0.5 
 
m
 
Ci/well, 2 Ci/
mmol) incorporation over the last 16 h of culture.
 
ELISA for the Detection of Cytokines and Igs.
 
For the detec-
tion of IFN-
 
g
 
, IL-4, and IL-5 in the cell culture supernatants
sandwich ELISAs with the following mAb recognizing two dif-
ferent epitopes of the respective lymphokines were used: biotiny-
lated rat anti–mouse IFN-
 
g
 
 (AN-18.17.24) and unconjugated rat
anti–mouse IFN-
 
g
 
 (R4-6A2), biotinylated rat anti–mouse IL-5
(TRFK4) and unconjugated rat anti–mouse IL-5 (TRFK5), and
biotinylated rat anti–mouse IL-4 (BVD6-24G2) and unconju-
gated rat anti–mouse IL-4 (BVD4-1D11) (all antibodies were
purchased from PharMingen, San Diego, CA). The assays were
performed in polyvinyl chloride microtiter plates (Dynatech, Den-
kendorf, Germany) according to the instructions of the mAb
manufacturer. The binding reactions were visualized with a con-
jugate of peroxidase-labeled streptavidin (Sigma Chemical Co.)
and the substrate ABTS (Sigma Chemical Co.). Absorbance was
read at 414 nm in an ELISA microplate reader (Anthos Hill,
Salzburg, Austria). For quantification of the cytokines in the cul-
ture supernatants, titrations were performed with murine rIFN-
 
g
 
(Sigma Chemical Co.), rIL-4, and rIL-5 (Genzyme Corp.).
OVA-specific Ig levels were determined by coating microtiter
plates with either OVA (10 
 
m
 
g/well) or anti-IgE (1 
 
m
 
g/ml; the
rat anti–mouse IgE mAb [3–11] was provided by C. Heusser, No-
vartis, Basel, Switzerland) and subsequently blocked with 10%
BSA for 60 min at room temperature (RT). Twofold dilutions of
serum were added and incubated for 2 h at RT. Appropriate dilu-
tions of detecting Ab- or OVA-labeled biotin (for the detection
of OVA-specific IgE) and peroxidase-labeled streptavidin (Sigma
Chemical Co.) were added for 1 h at RT. Anti–mouse IgG1 was
from Serotec (Oxford, UK) and anti–mouse IgG2a from Phar-
Mingen. The substrate ABTS (Sigma Chemical Co.) was used as
described above.
 
Histological and Hematological Analysis.
 
Tissues from BCG-infected
and OVA-immunized mice were fixed in 10% phosphate-buff-
ered formalin for 24 h and embedded in paraffin wax. Sections
(2–3 
 
m
 
m) were cut and stained using standard histological proto-
cols with hematoxylin and eosin. The stained sections were visu-
alized by light microscopy.
 
Enumeration of BCG in the Organs of the Infected Mice.
 
Organs
recovered from infected mice were homogenized in sterile water
containing 0.5% Tween 80 (Sigma Chemical Co.). Numbers of
viable mycobacteria in the lung, liver, and spleen were deter-
mined by plating serial 10-fold dilutions of organ homogenates
on Middlebrook 7H11 agar (Difco Laboratories, Detroit, MI)
supplemented with 10% Middlebrook OADC enrichment (Difco
Laboratories). Colonies were counted after 21 d of incubation at
37
 
8
 
C in 9% CO
 
2
 
.
 
Statistical Analysis.
 
Statistical significance was analyzed by the
Student’s 
 
t
 
 test.
 
Results
 
Intranasal Infection of Mice with BCG Leads to a Polarized
Th1 Immune Response in the Lung.
 
An intranasal infection
model for BCG was established to investigate whether Th1
immune responses would reduce the development of Th2
responses in the lung. For this purpose, mice were anesthe-
tized and intranasally inoculated with different infectious doses 
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of BCG. 2–3 wk after intranasal infection with either 2 
 
3
 
10
 
3
 
, 2 
 
3
 
 10
 
4
 
, or 2 
 
3
 
 10
 
5
 
 CFUs of BCG, distinct granulo-
mas could be detected within tissue sections from lungs. At
doses 
 
.
 
 5 
 
3
 
 10
 
5
 
 CFUs, small granulomas were also de-
tected in the liver and spleen (data not shown). Mice in-
fected with BCG cleared the mycobacteria from the lung,
liver, and spleen during the following weeks, with only a
few persisting mycobacteria present after 12 wk of infec-
tion (Fig. 1 
 
A
 
). After 2, 4, or 8 wk after infection, cells iso-
lated from the MLNs of killed mice were stimulated with
PPD from 
 
M. bovis.
 
 The antigen-specific activation with
PPD only resulted in the detection of IFN-
 
g
 
 with no IL-4
or IL-5 being detected (Fig. 1 
 
B
 
). No IL-4, and only very
low levels of IL-5, could be detected even after in vitro
polyclonal T cell stimulation with anti-CD3 and IL-2 (data
not shown). The T cell response to PPD was strongest after
2 wk and had subsided by 8–12 wk of infection, as demon-
strated by the kinetics of IFN-
 
g
 
 production by T cells and
in vitro PPD-specific proliferation (Fig. 1, 
 
B
 
 and 
 
C
 
). Taken
together, the results clearly demonstrate that intranasal in-
fection with BCG induces a Th1 immune response in the
lung.
 
BCG Infection in the Lung Strongly Suppresses the Develop-
ment of OVA-induced Airway Eosinophilia.
 
To investigate
the influence of a BCG infection on the development of an
OVA-specific Th2 response in the lung, an experimental
protocol was developed in which BCG-infected and OVA-
sensitized mice were airway challenged with OVA (Fig. 2).
Intranasal infections were performed using 2 
 
3
 
 10
 
5
 
 CFUs
of BCG as this dose results in a strongly polarized infection
in the lung, but does not cause systemic disease (see above).
A BCG infection 4 wk before OVA airway challenge had a
profound suppressive effect on the allergen-induced accu-
mulation of eosinophils into the lung (Fig. 3). The decrease
in eosinophils was accompanied by an increase in neutro-
phils, lymphocytes, and monocytes in the BAL fluid of BCG-
infected animals. Histological examinations of lung tissue
from mice treated with BCG and OVA or OVA alone con-
firmed the strong reduction in lung eosinophil numbers af-
ter BCG infection (data not shown). The closer the time of
BCG infection was to the OVA airway challenge, the more
pronounced the suppressive effect was on the lung eosino-
philia (Fig. 4 
 
A
 
). Interestingly, even 12 wk past the first in-
fection, a suppressive effect on eosinophil accumulation into
the lung could be observed.
Eosinophil recruitment and development is dependent
upon the secretion of IL-5 (21, 22). Therefore, it was in-
vestigated whether the BCG induced suppression of airway
eosinophilia was accompanied by reduction of Th2s pro-
ducing IL-5 in the lung. We found that BCG infection 1,
4, or 8 wk before OVA challenge resulted in marked re-
duction in IL-5 production by restimulated T cells from
the draining lymph node (Fig. 4 
 
B
 
). In the experiments
shown in Figs. 3 and 4, responses were measured 6 d after
Figure 1. Intranasal infection
of mice with BCG induces a
Th1 response in the lung. (A)
Mycobacterial clearance from
mice intranasally infected with 2
3 105 CFUs of BCG organisms.
The course of infection in the
lung (open squares), liver (open cir-
cles), and spleen (closed circles) was
followed over 12 wk after infec-
tion. Data shown are the mean
bacterial counts of tissues from
nine mice (three separate experi-
ments) with standard deviations.
(B) IFN-g, IL-4, and IL-5 pro-
duction by T cells from MLNs
after in vitro restimulation with
PPD. Single-cell suspensions (2
3 105/well) from total MLNs of
control and 2-, 4-, and 8-wk
postinfected mice, were stimu-
lated in vitro for 48 h with PPD
(10 mg/ml). The level of cyto-
kines present in the supernatants
was determined by ELISA.
Shown are the mean values of
three separate experiments with
standard deviation (for each ex-
periment lymph nodes from
three mice in each group were
pooled). (C) [3H]thymidine up-
take by mediastinal lymphocytes
of control and BCG-infected
mice after stimulation with PPD
or the lectin Con A. LN cells (2
3 105 cells/well) from unin-
fected and BCG-infected mice
were incubated with medium,
PPD (10 mg/ml), or Con A (5
mg/ml) for 40 h, and then pulsed
with [3H]thymidine for the last
16 h of the culture period. Mean
[3H]thymidine uptake of tripli-
cates with standard deviations are
shown. Uptake of [3H]thymidine was between 500 and 1,000 cpm in all
cultures containing cells and medium alone. The experiments were re-
peated three times with similar results. *P ,0.05, **P ,0.0001, com-
pared to values obtained in cultures containing cells from uninfected mice.
Figure 2. Experimental design used to investigate the influence of a
BCG infection on OVA-induced eosinophilia in the lung. Mice were sub-
jected to the OVA immunization scheme (see Materials and Methods)
and intranasally infected with 2 3 105 CFUs of BCG organisms 1, 4, 8, or
12 wk before intranasal OVA challenge.564 Mycobacterium bovis–BCG Infection Inhibits Lung Eosinophilia
OVA challenge, since both eosinophilia and T cell reactiv-
ity could readily be monitored at this time point. Eosino-
phil numbers and IL-5 production were similarly reduced
when the response was analyzed 3 or 10 d after OVA chal-
lenge in mice infected with BCG 4 wk before OVA airway
challenge (data not shown). These data further establish
that the observed reduction of airway eosinophilia and IL-5
production by T cells was not due to a shift in the kinetics
of the OVA-induced Th2 response.
Even though BCG infection had a suppressive effect on
both T cells secreting IL-5 and eosinophil accumulation
into the airways, OVA-specific IgG1, IgG2a, and IgE se-
rum levels were not reduced or altered (Fig. 5 A). Further-
more, in mice infected with BCG 1, 4, or 8 wk before
OVA challenge, blood eosinophilia was not reduced com-
pared to mice only immunized with OVA (Fig. 5 B).
BCG-induced Suppression of Airway Eosinophilia Was De-
pendent upon IFN-g Signaling and Could Be Reversed by Intra-
nasal Administration of IL-5. IFN-g has been shown to in-
hibit the development of Th2s (23–26). To address the
question of whether IFN-g was mediating the observed in-
hibition of airway eosinophilia, IFN-gR2/2 animals were
subjected to the OVA immunization protocol and infected
with BCG 2 wk before OVA challenge. The deletion of
the IFN-gR strongly reduced the BCG infection-induced
inhibition of airway eosinophilia (Fig. 6 A). In fact, as
could be predicted, the IFN-gR2/2 mice, but not controls
develop a slight lung eosinophilia after BCG infection.
Based on the results obtained in the IFN-gR2/2 mice, the
most likely explanation for our results is that IFN-g in-
duced by the BCG infection in the lung suppressed the de-
velopment or expansion of Th2s specific for OVA and se-
creting IL-5. To rule out the possibility that the BCG
infection directly interfered with eosinophil homing to the
Figure 3. Intranasal infection of BCG
strongly inhibits the development of airway
eosinophilia. OVA-immunized mice were
either intranasally infected with 2 3 105
CFUs of BCG 4 wk before OVA airway
challenge or left uninfected as an OVA con-
trol (see Fig. 2). 6 d after the OVA airway
challenge, a BAL was performed on both
groups of mice as well as unimmunized
mice. BAL cells were counted, stained with
haematoxylin and eosin, and the different
cell types were identified microscopically.
Shown are the average numbers of cells,
with standard deviation, present in the
BALs of the different groups of mice (five
mice per group). The experiments were re-
peated five times with similar results. *P
,0.01, compared to values obtained in un-
immunized mice.
Figure 4. BCG-induced suppression of airway eosinophilia and reduc-
tion of IL-5 secretion by T cells is dependent upon the elapsed time from
BCG infection. OVA-immunized mice were either subjected to BCG in-
fection at 1, 4, 8, or 12 wk before OVA airway challenge or left unin-
fected. Age-matched mice not subjected to the OVA immunization (Un-
immunized) were included as controls. 6 d after OVA airway challenge,
BALs were performed on each group of mice. Shown are the average
numbers of eosinophils present in the BALs of the different groups (n 5 5
for each group) of mice (A). In parallel to the BALs, single-cell suspen-
sions (2 3 105 cells/well) from MLNs of the different groups of mice
were prepared and stimulated in vitro for 48 h on anti-CD3–bound plates
in the presence of IL-2. Shown is the amount of IL-5 present in the MLN
cultures from three individual mice per group with standard deviation
(B). The experiments were repeated at least three times with similar re-
sults. *P ,0.05, **P ,0.0001, compared to values obtained in OVA only
immunized mice.565 Erb et al.
lung, we investigated whether the intranasal administration
of IL-5 could restore accumulation of eosinophils into the
airways of OVA-primed and BCG-infected mice. The in-
hibitory effect of a BCG infection on OVA-induced air-
way eosinophilia could be partially reversed by intranasal
administration of IL-5 to z20–25% of the level observed in
OVA only primed and airway-challenged mice (Fig. 6 B).
Reduction of Airway Eosinophilia Was Dependent upon the
Dose of Mycobacteria Used and the Route of Infection. In all
experiments shown so far, a standard dose of 2 3 105 BCG
organisms was used for the intranasal infections. To assess
the number of BCG organisms necessary to induce the
suppressive effect on the development of airway eosino-
philia, mice were infected with different doses of BCG and
subjected to the OVA immunization protocol. The use of
2 3 106 CFUs of BCG for infection 4 wk before OVA
challenge did not result in a higher degree of suppression
than did a dose of 2 3 105 organisms. However, the sup-
pressive effect was already markedly reduced using 2 3 104
and no longer detectable using 2 3 103 organisms (Fig. 7 A).
Moreover, the inhibitory effect of BCG infection on the
accumulation of eosinophils into the airways was depen-
dent upon the route of infection. Intranasal infection was
superior to intraperitoneal or subcutaneous infection in its
Figure 5. BCG infection of the lung did not alter the development of
OVA-specific IgG1, IgG2a, or IgE antibodies or blood eosinophilia. Mice
were treated as described in the legend to Fig. 3. Serum and blood smears
were prepared 10 d after OVA airway challenge and OVA-specific anti-
body levels were determined by ELISA (A). Values represent serum anti-
body titers from individual mice. Titers were determined by plotting A414
against the logarithm of the reciprocal of the serum dilution and taking
the midpoint of the linear section of the sigmoid curve produced. Blood
smears were stained with hematoxylin and eosin and the different cell types
were identified microscopically. Shown is the percentage of eosinophils
present in the blood of individual mice (B). As a control, sera and blood
smears from age-matched uninfected mice were also analyzed.
Figure 6. BCG-induced suppression of airway eosinophilia was depen-
dent upon IFN-g signaling and could be reversed by the administration of
IL-5. (A) 12 control (129/Sv/Ev) and 12 IFN-gR2/2 mice were sub-
jected to the OVA immunization protocol. From these mice, half were
also infected with 2 3 105 CFUs of BCG organisms 2 wk before OVA
airway challenge. 6 d after intranasal OVA challenge, BALs were per-
formed and numbers of eosinophils determined as described in the legend
to Fig. 3. As controls, BALs were also prepared from non–OVA-immu-
nized wild-type 129/Sv/Ev and IFN-gR2/2 mice that had been infected
with 2 3 105 BCG organisms for 20 d. Shown are the numbers of eosi-
nophils present in the BALs of six individual mice per group. (B) Four
groups of mice were subjected to the OVA immunization protocol, two
of which were also intranasally infected with 2 3 105 CFUs of BCG 4 wk
before OVA airway challenge. OVA-primed or OVA-primed and BCG-
infected mice were either intranasally challenged with OVA or with a
combination of OVA and IL-5 (500 units) and the numbers of eosinophils
present in the BALs were determined 6 d after airway challenge. Shown
are the numbers of eosinophils present in the BALs of six individual mice
per group. 
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ability to reduce airway eosinophilia (Fig. 7 
 
B
 
). Taken to-
gether, these experiments clearly demonstrate that the re-
duction in airway eosinophilia was both dependent upon
the amount of BCG organisms used and the route of infec-
tion.
 
BCG Infection in the Lung Partially Suppressed the Develop-
ment of Airway Eosinophilia Induced by N. brasiliensis Infec-
tion.
 
The Th2 response in the lung induced by OVA im-
munization leads to the secretion of relatively low levels of
IL-4 and IL-5 by T cells from the lung or MLNs after in
vitro stimulation (Fig. 4 
 
B
 
 and data not shown). We next
investigated whether BCG infections could also suppress
the development of a strong natural Th2 response induced
through the infection with the helminth 
 
N. brasiliensis.
 
 In-
tranasal BCG infections were able to suppress accumulation
of eosinophils into the lung after 
 
N. brasiliensis
 
 infection
(Fig. 8 
 
A
 
). However, the accumulation of eosinophils into
the lung was only strongly inhibited when the BCG infec-
tion was done 1 wk before the 
 
N. brasiliensis
 
 infection. In-
fection with BCG before 
 
N. brasiliensis
 
 only reduced eosi-
nophil numbers by 
 
z
 
50% and only 30% when performed 4
and 8 wk before the helminth infection, respectively. The
suppression of airway eosinophil accumulation correlated
strongly with a marked reduction in IL-4 and IL-5 produc-
tion by T cells from the MLNs, measured after in vitro
stimulation on anti-CD3–coated plates (Fig. 8 
 
B
 
). It clearly
appears that the closer the BCG infection was to that of 
 
N.
brasiliensis
 
, the less IL-4 and IL-5 could be detected in the
cultures of T cells from the MLNs.
Interestingly, the suppressive effect of a BCG infection
on a developing Th2 response in the lung was more pro-
nounced in the model of OVA-induced airway eosino-
philia than after 
 
N. brasiliensis
 
 infection. This demonstrates
that BCG infection can very efficiently inhibit the develop-
ment of airway eosinophilia induced by allergens, but not
as significantly as that induced by a helminth infection (Figs.
Figure 7.Inhibition of airway eosinophilia was both dependent upon
the dose and route of BCG infection. Mice were subjected to the OVA
immunization protocol and infected with different doses of BCG (A) or
with 2 3 105 CFUs of BCG organisms either intranasally, intraperito-
neally, or subcutaneously (B). All infections were performed 4 wk before
OVA airway challenge. 6 d after OVA airway challenge BALs were pre-
pared and treated as described in the legend to Fig. 3. Shown is the mean
inhibition with standard deviation of the response from five age-matched
mice. The experiments were repeated three times with similar results. *P
,0.01, **P ,0.0001, compared to percentage of inhibition using 2 3 106
BCGs (A) or intranasal infection (B).
Figure 8.Intranasal infection with BCG reduces airway eosinophilia
and the secetion of IL-4 and IL-5 by T cells after infection with the hel-
minth N. brasiliensis. Mice were intranasally infected with 2 3 105 CFUs
of BCG at the different time points indicated before intraperitoneal infec-
tion with 1,000 L3 larvae of N. brasiliensis. 10 d after N. brasiliensis infec-
tion, BAL and MLN cultures were prepared. Shown are the average
numbers with standard deviations of eosinophils present in the BALs of
five individual mice per group (A). MLN cells from the different groups
of mice were stimulated in vitro for 48 h on anti-CD3–bound plates in
the presence of IL-2. Shown is the mean amount of IL-4 and IL-5 pro-
duced by T cells in the MLN cultures from five individual mice per group
with standard deviations (B). The experiments were repeated three times
with similar results. *P ,0.01, *p,0.001, compared to values obtained in
cultures containing cells from mice only infected with N. brasiliensis.
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4 and 8). These findings suggest that the amount of IFN-g
induced by infection with BCG is sufficient to suppress the
relatively weak Th2 response induced by an OVA immu-
nization, but not the strong Th2 response induced by N.
brasiliensis infection.
Discussion
The results presented in this report clearly demonstrate
that BCG infection of the lung suppressed the develop-
ment of OVA-induced airway eosinophilia and support the
hypothesis that a reduction of infectious diseases may con-
tribute to the increase in severity and prevalence of atopic
disorders in humans. The closer in time the BCG infection
was to OVA challenge, the greater the degree of suppres-
sion of eosinophil accumulation in the airways. The inhibi-
tion of eosinophil accumulation in the airways correlated
with a reduction in the capacity of draining LN T cells to
produce IL-5 upon in vitro restimulation. Conversely, the
stronger the inhibition of airway eosinophilia, the less IL-5
could be detected. Furthermore, the inhibitory effect of
BCG on airway eosinophilia was dependent upon the dose
of infection, with BCG numbers >2 3 105 CFUs resulting
in maximal inhibition. The route of infection also influ-
enced BCG-induced suppression of airway eosinophilia,
with intranasal infection being superior to intraperitoneal
or subcutaneous infection in its ability to reduce airway
eosinophilia.
We used IFN-gR2/2 mice to investigate whether IFN-g
was the Th1-related cytokine responsible for the observed
inhibition of airway eosinophilia. IFN-gR2/2 mice receiv-
ing both the OVA immunization protocol and infection
with BCG developed profound airway eosinophilia indi-
cating that the BCG-induced inhibition was mediated by
IFN-g. However, the level of eosinophilia in the IFN-
gR2/2 mice infected with BCG was somewhat lower than
that detected in mutant mice only subjected to the OVA
immunization protocol. This indicates that other factors
besides IFN-g may play a role in the observed inhibition of
airway eosinophilia. Further analysis of the immune re-
sponse against BCG in IFN-gR2/2 mice revealed that a
background lung eosinophilia also developed, which was
not observed in uninfected mutant or control mice. The
Th2 response was characterized by T cells secreting IL-5
after PPD-specific activation in vitro, lung and blood eosi-
nophilia, and increased IgE serum levels (Erb, K.J., J. Kir-
man, B. Delahunt, and G. Le Gros, manuscript in prepara-
tion). This suggests that IFN-g expression generally leads
to the inhibition of Th2 immune responses in vivo. Our
observations are supported by previous reports showing that
IFN-g suppresses the development of Th2s both in vitro and
in vivo (23–26). Furthermore, IFN-g–mediated suppres-
sion of Th2 responses in the lung has also been docu-
mented (27–29). In view of these reports, the most likely
explanation for our results is that the production of IFN-g
during an active BCG infection blocks the expansion of
Th2s secreting IL-5 in the lung. Alternatively, the BCG in-
fection could directly interfere with the homing of Th2s
into the lung. Impaired homing of Th2s into inflamed sites
dominated by Th1 responses has recently been reported
(30). Irrespective of the underlying mechanism, reduction
of IL-5 production in the lung seems to be one of the ma-
jor factors responsible for the observed inhibition of airway
eosinophilia, since accumulation of eosinophils into the air-
ways is highly dependent upon IL-5 (21, 22) and adminis-
tration of IL-5 into the lung at least partly restored airway
eosinophilia (20–25% of the levels observed in control
mice). However, since IL-5 administration into the lung
did not totally restore eosinophil accumulation into the air-
ways, we cannot rule out that the BCG infection also in-
duced the production of some unknown factor thus con-
tributing to the observed suppression of airway eosinophilia.
Furthermore, MacLean et al. recently reported that the
production of the chemokine eotaxin, which leads to the
accumulation of eosinophils, was dependent upon Th2s
(31). The incomplete restoration of airway eosinophilia af-
ter IL-5 administration may therefore also reflect an eo-
taxin deficit induced by the BCG infection in the lung via
the suppression of Th2 development. Interestingly, BCG
infection 12 wk before OVA challenge still resulted in a
strong inhibition (60–70%) of airway eosinophilia. At this
time point, both the inflammatory and T cell response
against BCG had already largely subsided with only a few
persisting BCG organisms still detected in the lung.
One important therapeutic implication from our study is
that the suppressive effect of BCG infection on the OVA-
specific Th2 response was localized to the lung and did not
influence blood eosinophil or OVA-specific IgG1 or IgE
serum levels. This demonstrates that intranasal inoculation
with BCG only suppressed the local Th2 immune response
induced after OVA airway challenge and not the systemic
one induced by the intraperitoneal immunization with
OVA in alum adjuvant. In this context, it is important to
note that OVA airway challenge is not necessary to induce
the systemic Th2 response since blood eosinophilia and
OVA-specific IgE are already detectable before OVA-intrana-
sal challenge (our unpublished observation).
Szabo et al. recently published a report showing that IL-4
downmodulated the expression of the IL-12R b chain on
T cells in vitro (32). The authors suggest that this down-
modulation leads to the generation of Th2s, since they are
no longer responsive to IL-12–mediated signaling. Impor-
tantly, the presence of IFN-g inhibited this IL-4–induced
effect, thereby leading to the development of only Th1s.
The observed strong inhibition of the OVA-induced Th2
response in the lung could be due to this IFN-g–mediated
effect. However, the results of the N. brasiliensis experi-
ments lead us to the conclusion that the suppressive effect
of a BCG infection on airway eosinophilia can at least in
part be overridden by the induction of a strong Th2 re-
sponse. It is therefore tempting to speculate that the bal-
ance between IFN-g and IL-4 present at the site of T cell
activation determines whether Th1 and or Th2 cells are
generated, with high IL-4 levels being able to overcome
the inhibitory effect of IFN-g on Th2 development in
vivo. Supporting this view are results showing that infec-568 Mycobacterium bovis–BCG Infection Inhibits Lung Eosinophilia
tion of mice with respiratory syncytial virus, which induces
the production of IFN-g, did not inhibit eosinophilic in-
flammation into the airways after OVA sensitization (33).
Inhibition of airway eosinophilia might therefore be lim-
ited to mycobacterial infections that induce strong and rel-
atively long lasting IFN-g responses in the lung (14, 15).
In conclusion, our data demonstrate that a localized
BCG infection in the lungs of mice can inhibit the accu-
mulation of eosinophils into the airways and reduce the
amount of IL-5 secreted by the T cells from the MLNs,
and that the inhibitory effect was at least to a great degree
dependent upon IFN-g signaling and could be partially re-
versed by the presence of IL-5 in the lung. Importantly, an
allergic type Th2 response, induced by OVA immuniza-
tion, was more efficiently suppressed than an infectious
type induced by a helminth infection. Our results support
the hypothesis that infectious diseases of the lung may help
decrease the severity and prevalence of atopic disorders in
humans. Furthermore, BCG immunization of children may
potentially be helpful in reducing the risk of developing se-
vere asthma, which is strongly associated with eosinophil-
induced inflammation (3). However, the results presented
in this report suggest that for BCG to have the most pro-
nounced effect, it should be administered directly into the
lung. A recent report demonstrating that subcutaneous im-
munization of children with BCG had no inhibitory effect
on the development of asthma, suggests that this view may
be true (34).
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